{"id":12655,"date":"2026-05-28T21:11:00","date_gmt":"2026-05-28T19:11:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=40bc09e15cd4f1f359dbd1446003dd0e"},"modified":"2026-05-28T21:11:00","modified_gmt":"2026-05-28T19:11:00","slug":"medincell-videoconference-and-publication-of-annual-financial-results-tuesday-june-16-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=12655","title":{"rendered":"Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026"},"content":{"rendered":"

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.<\/p><\/a><\/a>

\nThe presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.<\/p>

\nVideoconference in English, 6:00pm CEST \/ 12:00pm ET\n<\/b>>https:\/\/www.medincell.com\/annual-results-2025-2026-register\/<\/a><\/p>

\nDuring the videoconference, Medincell\u2019s management team will provide an overview of the company\u2019s performance and strategic outlook, followed by a Q&A session in English.<\/p>

\nAbout Medincell<\/b><\/p>

\nMedincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.<\/p>

\nThese treatments combine active pharmaceutical ingredients with our proprietary BEPO\u00ae<\/sup> \/ BEPO\u00ae<\/sup> Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable depot.<\/p>

\nMedincell\u2019s investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.<\/p>

\nHeadquartered in Montpellier, France, Medincell employs over 140 people representing more than 25 nationalities.<\/p>

\nmedincell.com<\/a><\/b><\/p>

\nUZEDY\u00ae<\/sup> is a trademark of Teva Pharmaceuticals. Medincell\u2019s BEPO\u00ae<\/sup> technology is licensed to Teva as SteadyTeq\u2122, a trademark of Teva Pharmaceuticals.<\/i><\/p> Contacts<\/b>

\nDavid Heuz\u00e9<\/b>Head of Corporate and Financial Communications, and ESG\ndavid.heuze@Medincell.com<\/a> \/ +33 (0)6 83 25 21 86<\/p>

\nGrace Kim<\/b>Chief Strategy Officer, U.S. Finance\ngrace.kim@medincell.com<\/a> \/ +1 (646) 991-4023<\/p>

\nNicolas M\u00e9rigeau<\/b>Media Relations\nMedincell@newcap.eu<\/a> \/ +33 (0)1 44 71 94 94<\/p>

\nLouis-Victor Delouvrier \/ Alban Dufumier<\/b>Investor Relations France\nMedincell@newcap.eu<\/a> \/ +33 (0)1 44 71 94 94<\/p>","protected":false},"excerpt":{"rendered":"

MONTPELLIER, France–(BUSINESS WIRE)–Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12655","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12655"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12655\/revisions"}],"predecessor-version":[{"id":12656,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12655\/revisions\/12656"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}